Navigation Links
Study using stem cells to improve organ transplantation to receive $12 million

CHICAGO An innovative Northwestern Medicine research program investigating if stem cells may be the key to allowing organ transplant patients to stop taking immunosuppressive drugs has received $12 million in research funding. The grant will allow researchers to finish Phase II of the clinical trials and begin Phase III. Northwestern began the study's clinical trial in early 2009 as part of a partnership with the University of Louisville, which engineers the specialized stem cells used in each transplant procedure.

"During our clinical trials, we have been able to take the novel stem cell technology that the University of Louisville pioneered from the bench to the bedside," said Joseph Leventhal, MD PhD, director of kidney and pancreas transplantation at Northwestern Memorial Hospital, and professor of Surgery at Northwestern University Feinberg School of Medicine. "The results of our clinical trial were a catalyst for Novartis' long-term investment in this new cellular based therapy for solid organ transplantation."

The clinical trial uses specially engineered stem cells from kidney donors to make the organ recipient's immune system recognize the new kidney as its own. In mainstream transplant procedures, a recipient faces the danger of their immune system treating a newly transplanted organ as a foreign body that should be removed, causing it to attack and try to kill the new organ. To prevent a recipient's immune system from attacking their new organ, doctors must currently prescribe toxic anti-rejection medicines to weaken the immune system and keep it at bay.

In March of 2012, Leventhal and his colleagues published the study's initial clinical results from eight participants in Science Translational Medicine. The article outlined that of the study's eight participants, five were able to successfully stop taking all anti-rejection medicines in just one year after they received a new kidney, and two required only low-doses of anti-rejection medicine to be maintained instead of a normal regimen. The final patient suffered an unrelated illness that required another kidney transplant to be performed.

"Northwestern's Comprehensive Transplant Center has demonstrated for the first time in the history of organ transplantation that we can safely achieve durable transplantation tolerance in mismatched and unrelated donor/recipient combinations," said Leventhal. "I am very excited to be able to continue this groundbreaking translational research."

The first subjects to participate in the research study underwent surgery on February 26, 2009. To date, more than 20 patients have been enrolled and have received new kidneys as part of the clinical trial, the majority of which have been successfully taken off of all anti-rejection medicines. In order to qualify, the donor and recipient pairs must be blood-type compatible and have a negative cross-match, which means that testing has been done to confirm the recipient does not have antibodies in the blood that would cause rejection of the kidney.

The grant is a result of a license and research collaboration agreement between Regenerex LLC and Novartis to provide access to the novel technology developed by the University of Louisville's Institute for Cellular Therapeutics. Leventhal does not receive financial incentives or payment from Novartis or Regenerex LLC.


Contact: Bret Coons
Northwestern Memorial Hospital

Related medicine news :

1. FDA awards $2.25M grant to study immunosuppresive drug in high-risk patients
2. Study finds that Americans want doctors guidance on genetic test results
3. New study assesses injuries seen in the emergency department to children of teenage parents
4. Study Finds Infants Under 6 Months Too Young for Flu Shot at High Risk to Influenza Fatalities- UV Technologies Makers of UV-Aid, Develop New Flu Prevention Alternative
5. Independent Naturopathic Clinic Receives Groundbreaking Research Grant: Partners with Global Pharmaceutical Company to Study Relief of Cancer Drug Side Effects
6. 20 percent of nations GME funds go to New York while 29 states get less than 1 percent, study says
7. Physician shortage could be cut by new primary care models, study finds
8. Study: Access to health care increases prescription opioid availability and associated abuse
9. Study: Higher rates of diabetes, hypertension, heart disease and stroke found in food desert
10. U-M study: Smarter blood pressure guidelines could prevent many more heart attacks and strokes
11. Study looks at safety, effectiveness of generics for treating depression
Post Your Comments:
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... technologies and development solutions for drugs, biologics, consumer health and animal health products, ... Technology, and will lead a new, dedicated global team of drug development and ...
(Date:10/12/2015)... ... October 13, 2015 , ... North American Tool Corporation has been named ... National Meeting in Rosemont, IL on October 4th. , Each year, ... excellence that customers have come to expect from members of IBC’s marketing group. ...
(Date:10/12/2015)... ... October 12, 2015 , ... Amerec , a leader in ... and skin care equipment, will be displaying custom sauna and steam room solutions at ... high-end resorts and spas as customers, SpaEquip is recognized for their ability to assist ...
(Date:10/12/2015)... , ... October 12, 2015 , ... American Family Care ... expand its footprint by opening its 151st medical center. Located at 606A Boll Weevil ... “We’re excited to continue fulfilling our mission of making quality health care accessible and ...
(Date:10/12/2015)... USA (PRWEB) , ... October 12, 2015 , ... ... personal audio products, will present the latest version of Companion Mics, the CM•4 ... audiometry, at the European Union of Hearing Aid Acousticians’ (EUHA) 60th Annual Congress ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... 2015 ,The  pharma  ADMET ... as they look to implement more-predictive ADMET testing. ... new report by  visiongain . --> ... from pharmaceutical companies as they look to implement ... appear in a new report by  visiongain . ...
(Date:10/12/2015)...  Today, Divurgent is honored to announce Paul Anderson ... CIO, Paul brings 15 years of hands-on experience as a ... today,s CIOs, he is one. The challenges that face today,s ... and his new role with Divurgent allows him to lead ... organization. ...
(Date:10/12/2015)... Beginning October 1, 2015 All HIPAA Covered ... growing practice management system for therapists, psychologists, and psychiatrists ... patient diagnostic codes from the former DSM-4/ICD-9, to the ... --> Therapy Partner has also generated a ... to easily understand the conversion to ICD-10 codes; this ...
Breaking Medicine Technology: